Category | Â | Number | Percentage |
---|---|---|---|
Age (mean ± SD) |  | 49.4 ± 10.7 years | |
Pretreatment size (mean ± SD) |  | 5.6 ± 2.8 cm | |
Chemotherapy regimen | Â | ||
Dose dense AC-T | 50 | 48.6 | |
AC-T | 18 | 17.5 | |
FEC-D | 29 | 28.2 | |
ED | 1 | 1.0 | |
TC | 4 | 3.9 | |
Estrogen Receptor Status | Â | ||
Positive | 66 | 64.1 | |
Negative | 37 | 35.9 | |
Progesterone receptor status | Â | ||
Positive | 58 | 56.3 | |
Negative | 45 | 43.7 | |
HER2 receptor status | Â | ||
Positive | 32 | 31.1 | |
Negative | 71 | 68.9 | |
Classification | Â | ||
Luminal A | 30 | 29.1 | |
Luminal B (HER2-negative) | 17 | 16.5 | |
Luminal B (HER2-positive) | 18 | 17.5 | |
HER2 positive | 13 | 12.6 | |
Triple-negative | 24 | 23.3 | |
Laterality | Â | ||
Left | 47 | 45.6 | |
Right | 55 | 35.4 | |
Bilateral | 1 | 1.0 | |
Menopausal status | Â | ||
Pre-menopausal | 57 | 55.3 | |
Post-menopausal | 37 | 35.9 | |
Peri-menopausal | 7 | 6.8 | |
Not available | 2 | 1.9 | |
Histology | Â | ||
IDC | 97 | 94.2 | |
ILC | 3 | 2.9 | |
IMC | 1 | 1.0 | |
Mixed ILC/IDC | 2 | 1.9 | |
Lymphovascular invasion | Â | ||
Negative | 50 | 48.5 | |
Positive | 45 | 43.7 | |
Not available | 8 | 7.8 | |
TÂ (tumor) stage | Â | ||
T1 | 2 | 1.9 | |
T2 | 44 | 42.7 | |
T3 | 46 | 44.7 | |
T4 | 11 | 10.7 | |
Clinical N (nodal)Â stage | Â | ||
N0 | 28 | 27.2 | |
N1 | 62 | 60.2 | |
N2 | 12 | 11.7 | |
N3 | 1 | 1.0 | |
Stage group | Â | ||
IIA | 16 | 15.5 | |
IIB | 37 | 35.9 | |
IIIA | 38 | 6.9 | |
IIIB | 11 | 10.7 | |
IIIC | 1 | 1.0 | |
Pathologic N (nodal) status | Â | ||
Negative | 10 | 9.7 | |
Positive | 80 | 77.7 | |
N/A | 13 | 12.6 |